BioTheryX, Inc. Announces the Appointment of BioPharma Finance Veteran Peter N. Crnkovich to Board of Directors

Part of BioTheryX’s previously announced plan to continue building out its Board of Directors with key industry leaders now that Company has transitioned from preclinical to clinical with lead Acute Myeloid Leukemia (“AML”) compound BTX-A51

CHAPPAQUA, N.Y., Nov. 11, 2019 /PRNewswire/ — BioTheryX, Inc. (“BioTheryX”), a clinical stage biotechnology company creating new classes of drugs for unmet medical needs based on targeted protein degradation and multi-kinase inhibition, today announced the appointment of Peter N. Crnkovich to its Board of Directors. Since September 2018 Mr. Crnkovich has served as a Senior Consultant at the Company. Mr. Crnkovich currently serves as a Senior Advisor at Morgan Stanley, and prior to his retirement from Morgan Stanley after 34 years, he held a variety of positions there, including most recently as Chairman of the Global Health Care Group in investment banking for over a decade. Mr. Crnkovich is also a Senior Advisor at Riboscience LLC, an emerging biopharmaceutical company. Mr. Crnkovich received a B.S. from Georgetown University and an MBA from the Stanford Graduate School of Business.

“We are delighted to add Peter Crnkovich as a Director of BioTheryX,” said David Stirling, CEO and Founder of BioTheryX. “His vast experience in the biopharma capital markets and as a strategic advisor to companies in the biopharma industry will be of tremendous value as BioTheryX enters the clinic with its lead multi-kinase inhibitor, and drives forward its first-in-class “molecular glue” Protein Homeostatic Modulators (“PHMs®”) and bifunctional protein degraders.”

In addition to Mr. Crnkovich, the BioTheryX Board currently includes:

  • David Stirling, PhD – CEO/Founder, Co-founder and former CSO of Celgene, repositioned thalidomide as a breakthrough therapy for cancer, myelodysplastic syndrome and related conditions. Developed Celgene into a top-tier pharmaceutical business. Led effort to develop a class of antiproliferative and immunomodulatory drugs such as the targeted protein degrading “molecular glues” THALOMID®, REVLIMID®, POMALYST®, as well as the psoriatic arthritis drug OTEZLA® and the ADHD drug FOCALIN®
  • Lawrence Zaslow, MBA – President/Founder, founding Managing Director of Amphion Innovations
  • Louis DeGennaro, PhD – CEO/President of Leukemia & Lymphoma Society
  • Jeffrey L. Edwards – Former CFO of Allergan, Inc.